Boscia Giacomo, Viggiano Pasquale, Marzulli Federica, Grassi Maria Oliva, Puzo Pasquale, Dore Stefano, Pinna Antonio, Alessio Giovanni, Boscia Francesco
Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Clin Ophthalmol. 2023 Jul 17;17:2003-2012. doi: 10.2147/OPTH.S411094. eCollection 2023.
To assess the long-term morpho-functional retinal and choroidal changes in chronic central serous chorioretinopathy (cCSC) pachychoroid eyes in response to continuous oral eplerenone (EPL) treatment.
This pilot study was conducted on patients with unilateral exudative cCSC. We enrolled a total of 17 exudative cCSC and 17 non-exudative fellow eyes of 17 patients. Baseline best-corrected visual acuity (BCVA) and anatomical (structural optical coherence tomography [OCT] and OCT angiography) parameters in both eyes were collected at baseline. Follow-up data were collected at 6, 12, and 48 months after initiation of EPL treatment.
(i) Exudative cCSC eyes: Compared with baseline (0.34±0.13 LogMAR), BCVA significantly improved at follow-up examinations (6 months: 0.28±0.13 LogMAR, p=0.039; 12 months: 0.22±0.11 LogMAR, p=0.025; 48 months: 0.21±0.08 LogMAR, p=0.028). Furthermore, there was a significant reduction from baseline in all structural OCT parameters (subretinal fluid and subfoveal choroidal thickness [SFCT]; p<0.05). (ii) Non-exudative fellow eyes: There was no significant change in BCVA. There was a significant reduction from baseline in SFCT and choriocapillaris flow deficit percentage (p<0.05).
In this pilot study, continuous oral EPL therapy in cCSC pachychoroid eyes resulted in long-term morpho-functional improvement. The beneficial effect of EPL occurred within the first year and was maintained after four years. Based on these preliminary observations, EPL may be effective in the exudative forms of CSC.
评估慢性中心性浆液性脉络膜视网膜病变(cCSC)厚脉络膜眼在持续口服依普利酮(EPL)治疗后视网膜和脉络膜的长期形态功能变化。
本前瞻性研究针对单侧渗出性cCSC患者开展。共纳入17例患者的17只渗出性cCSC眼和17只对侧非渗出性眼。在基线时收集双眼的最佳矫正视力(BCVA)以及解剖学参数(结构光学相干断层扫描[OCT]和OCT血管造影)。在开始EPL治疗后的6个月、12个月和48个月收集随访数据。
(i)渗出性cCSC眼:与基线时(0.34±0.13 LogMAR)相比,随访时BCVA显著改善(6个月:0.28±0.13 LogMAR,p = 0.039;12个月:0.22±0.11 LogMAR,p = 0.025;48个月:0.21±0.08 LogMAR,p = 0.028)。此外,所有结构OCT参数(视网膜下液和黄斑中心凹脉络膜厚度[SFCT])均较基线时显著降低(p<0.05)。(ii)非渗出性对侧眼:BCVA无显著变化。SFCT和脉络膜毛细血管血流缺损百分比较基线时显著降低(p<0.05)。
在本前瞻性研究中,cCSC厚脉络膜眼持续口服EPL治疗可带来长期的形态功能改善。EPL的有益效果在第一年内出现,并在四年后得以维持。基于这些初步观察结果,EPL可能对渗出性CSC有效。